Molecular mechanisms of curcumin action: signal transduction
/in Curcuma, International Publications /von 2013-01-10 / Biofactors 2013 Jan-Feb;39(1):27-36Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2013-01-01 / Oncoimmunology 2013 Jan;2(1):e22664Oncothermia: a new paradigm and promising method in cancer therapies
/in Hyperthermia, International Publications /von 2013-01-01 / Acupunct Electrother Res 2013;38(3-4):161-97A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report
/in Hyperthermia, International Publications, Malignant Pleural Mesothelioma /von 2012-12-28 / J Med Case Rep 2012 Dec;6:427α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
/in Dendritic Cells, Glioblastoma, International Publications /von 2012-12-27 / BMC Cancer 2012 Dec;12:623Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2012-12-17 / Int J Hyperthermia 2013;29(1):8-16The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-72Short-term hyperthermia promotes the sensitivity of MCF-7 human breast cancer cells to paclitaxel
/in Breast Cancer, Hyperthermia, International Publications /von 2012-12-11 / Biol. Pharm. Bull. 2013;36(3):376-83Immunotherapy with tumor vaccines for the treatment of malignant gliomas
/in Glioblastoma, International Publications /von 2012-12-01 / Curr Drug Discov Technol 2012 Dec;9(4):237-55
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de